A Multicenter, Single-Arm, Open-Label, Phase 2 Study of Apitolisib (GDC-0980) for the Treatment of Recurrent or Persistent Endometrial Carcinoma (MAGGIE study)

Por Makker, Vicky, Recio, Fernando O., Ma, Ling, Matulonis, Ursula, Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston N., Ware, Joseph A., Zhu, Rui, Lu, Shan, Huw, Ling-Yuh, Wang, Yulei, Koeppen, Hartmut, Spoerke, Jill M., Lackner, Mark R., Aghajanian, Carol
Publicado no Cancer (2016)

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

Por Wilson, Timothy R, Yu, Jianjun, Lu, Xuyang, Spoerke, Jill M, Xiao, Yuanyuan, O’Brien, Carol, Savage, Heidi M, Huw, Ling-Yuh, Zou, Wei, Koeppen, Hartmut, Forrest, William F, Fridlyand, Jane, Fu, Ling, Tam, Rachel, Schleifman, Erica B, Sumiyoshi, Teiko, Molinero, Luciana, Hampton, Garret M, O’Shaughnessy, Joyce A, Lackner, Mark R
Publicado no NPJ Breast Cancer (2016)

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re...

Por Powles, Thomas, Lackner, Mark R., Oudard, Stéphane, Escudier, Bernard, Ralph, Christy, Brown, Janet E., Hawkins, Robert E., Castellano, Daniel, Rini, Brian I., Staehler, Michael D., Ravaud, Alain, Lin, Wei, O’Keeffe, Bridget, Wang, Yulei, Lu, Shan, Spoerke, Jill M., Huw, Ling-Yuh, Byrtek, Michelle, Zhu, Rui, Ware, Joseph A., Motzer, Robert J.
Publicado no J Clin Oncol (2016)